219 related articles for article (PubMed ID: 17991430)
1. The antilipolytic action of bis(alpha-furancarboxylato)oxovanadium(IV) in adipocytes.
Gao L; Niu Y; Liu W; Xie M; Liu X; Chen Z; Li L
Clin Chim Acta; 2008 Feb; 388(1-2):89-94. PubMed ID: 17991430
[TBL] [Abstract][Full Text] [Related]
2. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on non-diabetic and streptozotocin-diabetic rats.
Gao LH; Liu WP; Wang BL; Li L; Xie MJ; Li YR; Chen ZH; Chen XZ
Clin Chim Acta; 2006 Jun; 368(1-2):173-8. PubMed ID: 16487949
[TBL] [Abstract][Full Text] [Related]
3. [Insulino-mimetic effects of bis (alpha-furancarboxylato) oxovanadium (IV) in vitro].
Li YR; Gao LH; Ma YL; Niu YF; Liu WP; Li L
Yao Xue Xue Bao; 2008 Mar; 43(3):318-22. PubMed ID: 18630272
[TBL] [Abstract][Full Text] [Related]
4. Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes.
Zuo YQ; Liu WP; Niu YF; Tian CF; Xie MJ; Chen XZ; Li L
J Pharm Pharmacol; 2008 Oct; 60(10):1335-40. PubMed ID: 18812026
[TBL] [Abstract][Full Text] [Related]
5. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
[TBL] [Abstract][Full Text] [Related]
6. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes.
Reed MJ; Meszaros K; Entes LJ; Claypool MD; Pinkett JG; Brignetti D; Luo J; Khandwala A; Reaven GM
Diabetologia; 1999 Jan; 42(1):102-6. PubMed ID: 10027587
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats.
Dhalla AK; Santikul M; Chisholm JW; Belardinelli L; Reaven GM
Diabetes Obes Metab; 2009 Feb; 11(2):95-101. PubMed ID: 18494808
[TBL] [Abstract][Full Text] [Related]
8. Effects of new hypoglycemic agent A-4166 on lipolysis and lipogenesis in rat adipocytes.
Macho L; Fickova M; Zorad S; Sebokova E; Klimes I
Endocr Regul; 2000 Sep; 34(3):119-26. PubMed ID: 11074662
[TBL] [Abstract][Full Text] [Related]
9. Orally active and long-term acting insulin-mimetic vanadyl complex:bis(picolinato)oxovanadium (IV).
Sakurai H; Fujii K; Watanabe H; Tamura H
Biochem Biophys Res Commun; 1995 Sep; 214(3):1095-101. PubMed ID: 7575515
[TBL] [Abstract][Full Text] [Related]
10. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities.
Yamaguchi M; Wakasugi K; Saito R; Adachi Y; Yoshikawa Y; Sakurai H; Katoh A
J Inorg Biochem; 2006 Feb; 100(2):260-9. PubMed ID: 16387366
[TBL] [Abstract][Full Text] [Related]
11. Novel vanadyl complexes with quinoxaline N(1),N(4)-dioxide derivatives as potent in vitro insulin-mimetic compounds.
Noblía P; Vieites M; Torre MH; Costa-Filho AJ; Cerecetto H; González M; Lavaggi ML; Adachi Y; Sakurai H; Gambino D
J Inorg Biochem; 2006 Feb; 100(2):281-7. PubMed ID: 16386797
[TBL] [Abstract][Full Text] [Related]
12. Bis(α-furancarboxylato)oxovanadium(IV) exerts durable antidiabetic effects and suppresses matrix metalloproteinase-2 activity in spontaneous type 2 diabetic KKAy mice.
Li L; Gao L; Liu S; Liu Q; Sun S; Huan Y; Li C; Peng J; Hou G; Li L; Liu W; Shen Z
Biol Trace Elem Res; 2013 Jun; 153(1-3):329-39. PubMed ID: 23649370
[TBL] [Abstract][Full Text] [Related]
13. Effect of bis[curcumino]oxovanadium complex on non-diabetic and streptozotocin-induced diabetic rats.
Majithiya JB; Balaraman R; Giridhar R; Yadav MR
J Trace Elem Med Biol; 2005; 18(3):211-7. PubMed ID: 15966569
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
Thompson KH; Liboiron BD; Sun Y; Bellman KD; Setyawati IA; Patrick BO; Karunaratne V; Rawji G; Wheeler J; Sutton K; Bhanot S; Cassidy C; McNeill JH; Yuen VG; Orvig C
J Biol Inorg Chem; 2003 Jan; 8(1-2):66-74. PubMed ID: 12459900
[TBL] [Abstract][Full Text] [Related]
15. In vivo metabolic effects of naringenin in the ethanol consuming rat and the effect of naringenin on adipocytes in vitro.
Szkudelska K; Nogowski L; Nowicka E; Szkudelski T
J Anim Physiol Anim Nutr (Berl); 2007 Apr; 91(3-4):91-9. PubMed ID: 17355338
[TBL] [Abstract][Full Text] [Related]
16. Lack of the effect of mycotoxins-aflatoxin B1 and ochratoxin A on some functions of rat adipocytes.
Szkudelska K; Drzymała H; Szkudelski T; Bukowska K; Nogowski L
Toxicol In Vitro; 2005 Sep; 19(6):771-7. PubMed ID: 15963681
[TBL] [Abstract][Full Text] [Related]
17. Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes.
Kawabe K; Yoshikawa Y; Adachi Y; Sakurai H
Life Sci; 2006 May; 78(24):2860-6. PubMed ID: 16337244
[TBL] [Abstract][Full Text] [Related]
18. The influence of a new vanadium compound, bis(2,2'-bipyridine)oxovanadium(IV) sulphate on liver golgi complexes from control and streptozotocin-diabetic rats.
Kordowiak AM; Dabroś W; Kajda B
Horm Metab Res; 2002 Oct; 34(10):556-60. PubMed ID: 12439783
[TBL] [Abstract][Full Text] [Related]
19. A new orally active antidiabetic vanadyl complex--bis(alpha-furancarboxylato)oxovanadium(IV).
Xie M; Gao L; Li L; Liu W; Yan S
J Inorg Biochem; 2005 Feb; 99(2):546-51. PubMed ID: 15621288
[TBL] [Abstract][Full Text] [Related]
20. Effects of lipolytic and antilipolytic agents on glycerol and free fatty acid release from isolated adipocytes of normal and diabetic rats.
Kamei I; Hotta N; Kakuta H; Kimura M; Fukasawa H; Koh N; Sakamoto N
Nagoya J Med Sci; 1989 Mar; 51(1-4):17-23. PubMed ID: 2549422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
